Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03551821|
Recruitment Status : Recruiting
First Posted : June 11, 2018
Last Update Posted : June 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Alopecia Areata Alopecia Totalis Alopecia Universalis||Drug: ATI-50002||Phase 2|
This is an open-label study which will be conducted at 1 to 2 sites.
Subjects will be required to have a clinical diagnosis of AA, AU or AT with unilateral or bilateral loss of eyebrow hair.
Subjects will apply study medication to the entire affected eyebrow(s), twice-daily for 24 weeks.
Safety and tolerability will be evaluated throughout the study.
The duration of the study participation is anticipated to be a maximum of 233 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Eyebrow Loss Due to Alopecia Areata, Alopecia Universalis or Alopecia Totalis|
|Actual Study Start Date :||April 11, 2018|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: ATI-50002 Topical Solution
ATI-50002 Topical Solution
- Clinician's Eyebrow Assessment [ Time Frame: Six months ]Determination of the amount of hair in the affected area.
- Subject's Eyebrow Assessment [ Time Frame: Six months ]Determination of the amount of hair in the affected area.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03551821
|United States, Florida|
|Aclaris Investigator Site||Recruiting|
|Boynton Beach, Florida, United States, 33472|
|Contact: Susan Moran, RN 484-329-2129 firstname.lastname@example.org|